David Dornan brings more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies. His research has focused on diverse therapeutic modalities that target cancer vulnerabilities, modulate the immune system and deliver cytotoxic payloads to cancer cells via ADCs. Prior to Aadi, David served as Chief Scientific Officer at Elevation Oncology, where he led the scientific strategy and enabled the company’s pivot to a portfolio of ADCs. Before that, David was the Chief Scientific Officer at Bolt Biotherapeutics where he led research and development of novel immune-stimulating ADCs. Prior to this he headed Oncology Research at Gilead Sciences, where he oversaw the identification, validation and translation of oncogenic targets into biologic and small molecule therapeutics, as well as led the integrated oncology strategy team. David began his industry career at Genentech, spending a decade in roles of increasing responsibility and contributing significantly to target discovery, validation, and translational research initiatives. David received his PhD from the University of Dundee in Molecular Oncology and Biochemistry and completed a postdoctoral fellowship at Genentech.